Orexo AB Announces Extraordinary General Meeting in Uppsala

Orexo AB, a pharmaceutical company based in Uppsala, Sweden, has recently announced an Extraordinary General Meeting to be held on October 26, 2023. The meeting will take place at Advokatfirman Vinge’s premises in Stockholm, Sweden.

Shareholders who wish to participate in the General Meeting must be recorded as shareholders in the share register maintained by Euroclear Sweden AB by October 18, 2023. They are required to provide notice of participation no later than October 20, 2023, through post, email, or telephone.

The proposed agenda for the meeting includes the election of the chairman, the board of directors, and auditors. The nomination committee of Orexo has put forth proposals, including the appointment of Henrik Kjær Hansen as the chairman of the nomination committee for the Annual General Meeting in 2024. Additionally, Robin Evers has been proposed as a new member of the board of directors. Evers brings over 30 years of experience in Research and Development and currently holds a senior executive position at Novo Nordisk A/S.

Shareholders also have the right to obtain information from the board of directors and CEO during the General Meeting. They can submit questions in advance by post or email.

Orexo AB has provided supporting documents for the meeting, which are available at their office in Uppsala and on their website. Shareholders can request copies of these documents if needed.

For more information, shareholders can contact Lena Wange, IR & Communications Director of Orexo AB.

The Extraordinary General Meeting of Orexo AB signifies the company’s commitment to transparency and shareholder engagement. By providing an opportunity for shareholders to participate and make informed decisions, Orexo aims to strengthen its corporate governance and drive sustainable growth in the pharmaceutical industry.